Evidence map›Paper›PMID 41471159›Full record

ArticlePathogens (Basel, Switzerland)2025

Efficacy of Isoniazid-Rifampicin Preventive Therapy in Adolescent Contacts in School Outbreaks: A Retrospective Cohort Study in Eastern China.

Zhan Wang, Rong Wang, Wenjin Wang, Wenxin Jiang, Xinru Fei, Jingxian Ning, Yuchen Pan, Limei Zhu, Wei Lu, Qiao Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhan WangDepartment of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing 210009, China.ORCID 0009-0009-6313-6355
Rong WangDepartment of Chronic Communicable Disease, Nanjing Municipal Center for Disease Control and Prevention, Nanjing 210003, China.
Wenjin WangDepartment of Communicable Disease, Center for Disease Control and Prevention of Yancheng City, Yancheng 224000, China.
Wenxin JiangDepartment of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing 210009, China.
Xinru FeiDepartment of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing 210009, China.
Jingxian NingDepartment of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing 210009, China.
Yuchen PanDepartment of Epidemiology, School of Public Health, Southeast University, Nanjing 210009, China.
Limei ZhuDepartment of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing 210009, China.
Wei LuDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China.
Qiao LiuDepartment of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing 210009, China.ORCID 0000-0002-3572-133X

Funding

Jiangsu Provincial Medical Key Discipline ZDXK202250Key Scientific Research Project of Jiangsu Provincial Health Commission ZD2021052
6 · The paper itself

Abstract

Adolescents are underprioritized in tuberculosis (TB) control, and the effect of TB preventive therapy (TPT) in this group is unstudied in China. This study evaluated the protective effect of TPT in Chinese adolescents during TB outbreaks. Data on TB outbreaks and contact screening in six cities (2019-2021) were collected. Adolescents eligible for TPT were identified via tuberculin skin test or interferon-gamma assay and grouped by TPT. Follow-up until 31 December 2023, tracked TB onset. The protective effect was analyzed using KM survival curves and COX models. From January 2019 to December 2021, 136 school TB outbreaks were reported, involving 10,837 adolescent contacts. Among these, 624 adolescent contacts met the criteria for TPT (latent TB infection) at baseline; 277 (44.4%) initiated a 3-month isoniazid plus rifampicin preventive therapy (TPT group), while 347 (55.6%) did not receive TPT (non-TPT group). By 31 December 2023, 11 of these 624 adolescent contacts developed active TB, with 1 patient in the TPT group and 10 patients in the non-TPT group. The cumulative incidence of TB was 0.36% in the TPT group vs. 2.88% in the non-TPT group (χ

Indexed as

Antitubercular AgentsDisease OutbreaksIsoniazidRifampinTuberculosisAdolescentChildChinaContact TracingFemaleHumansIncidenceLatent TuberculosisMaleRetrospective StudiesSchoolsAntitubercular AgentsIsoniazidRifampinadolescent contactslatent tuberculosis infectionschool outbreakstuberculosis preventive therapy

Identifiers

PMID41471159
PMCPMC12735544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.